+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 2Years - 90Years
All Genders
ID06213636

Phase 12 Study of CD19CD22 CAR T-cell Therapy with Chemotherapy for Patients Aged 2 to 90 with Relapsed or Refractory B-cell Leukemia and Lymphoma

Led by Essen Biotech · Updated on 2025-08-06

75

Participants Needed

1

Research Sites

95 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a new form of immunotherapy using Human CD19-CD22 Targeted T Cells for patients with relapsed or refractory B-cell blood cancers, including various leukemias and lymphomas. This phase I trial aims to evaluate the safety, tolerability, and behavior of these specially engineered T cells in the body, as well as to determine the best dose and schedule for future studies. The trial also includes patients with central nervous system lymphoma and other related blood cancers, with comprehensive assessments to confirm eligibility. Participants will first receive chemotherapy to prepare their immune system before the infusion of the CD19-CD22 CAR-T cells. The chemotherapy includes intravenous fludarabine phosphate over several days and cyclophosphamide on a specific day, followed by an intravenous infusion of the CAR-T cells. Those who respond well and tolerate the treatment without serious side effects may receive two or three additional doses. The infusion process and chemotherapy are carefully timed and monitored. During the study, participants will undergo thorough monitoring including physical exams, blood tests, and imaging scans such as CT, MRI, and PET to evaluate the treatments effects and safety. Monitoring for side effects will continue closely, sometimes during hospitalization. The main outcome measured is the occurrence and severity of toxic effects within 28 days after infusion. The trial will also assess the ability to produce the CAR-T cells successfully. The overall study duration and follow-up are designed to ensure detailed observation of treatment responses and safety.

CONDITIONS

Brief Title

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Research Team

R

Rhoda M Smith, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here